H
Hua Yang
Researcher at Agios Pharmaceuticals
Publications - 74
Citations - 5568
Hua Yang is an academic researcher from Agios Pharmaceuticals. The author has contributed to research in topics: Pharmacodynamics & Pharmacokinetics. The author has an hindex of 21, co-authored 63 publications receiving 4509 citations.
Papers
More filters
Journal ArticleDOI
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle,Janeta Popovici-Muller,Nicolaos Palaskas,Sevin Turcan,Christian Grommes,Carl Campos,Jennifer Tsoi,Owen Clark,Barbara Oldrini,Evangelia Komisopoulou,Kaiko Kunii,Alicia Pedraza,Stefanie Schalm,Lee Silverman,Alexandra Miller,Fang Wang,Hua Yang,Yue Chen,Andrew Kernytsky,Marc K. Rosenblum,Wei Liu,Scott A. Biller,Shinsan M. Su,Cameron Brennan,Timothy A. Chan,Thomas G. Graeber,Katharine E. Yen,Ingo K. Mellinghoff,Ingo K. Mellinghoff +28 more
TL;DR: The recent discovery of mutations in metabolic enzymes has rekindled interest in harnessing the altered metabolism of cancer cells for cancer therapy, and isocitrate dehydrogenase 1 (IDH1), which is mutated in multiple human cancers, is examined.
Journal ArticleDOI
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Courtney D. DiNardo,Eytan M. Stein,S. de Botton,Gail J. Roboz,Jessica K. Altman,Alice S. Mims,Ronan T. Swords,Robert H. Collins,Gabriel N. Mannis,Daniel A. Pollyea,William B. Donnellan,Amir T. Fathi,A. Pigneux,Harry P. Erba,Gabrielle T. Prince,Anthony S. Stein,Geoffrey L. Uy,James M. Foran,Elie Traer,Robert K. Stuart,Martha Arellano,James L. Slack,Mikkael A. Sekeres,Christophe Willekens,Sung Choe,Hongfang Wang,Vickie Zhang,Katharine E. Yen,Stephanie M. Kapsalis,Hua Yang,David Dai,Bin Fan,Meredith Goldwasser,Hua Liu,Samuel V. Agresta,Bin Wu,Eyal C. Attar,Martin S. Tallman,Richard Stone,Hagop M. Kantarjian +39 more
TL;DR: In patients with advanced IDH1‐mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment‐related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission.
Journal ArticleDOI
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang,Jeremy Travins,Byron DeLaBarre,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Stefanie Schalm,Erica Hansen,Kimberly Straley,Andrew Kernytsky,Wei Liu,Camelia Gliser,Hua Yang,Stefan Gross,Erin Artin,Véronique Saada,Elena Mylonas,Elena Mylonas,Elena Mylonas,Cyril Quivoron,Cyril Quivoron,Cyril Quivoron,Janeta Popovici-Muller,Jeffrey O. Saunders,Francesco G. Salituro,Shunqi Yan,Stuart Murray,Wentao Wei,Yi Gao,Lenny Dang,Marion Dorsch,Sam Agresta,David P. Schenkein,Scott A. Biller,Shinsan M. Su,Stéphane de Botton,Stéphane de Botton,Stéphane de Botton,Katharine E. Yen +38 more
TL;DR: Evidence is provided that inhibitors targeting mutant IDH2/R140Q could have potential applications as a differentiation therapy for cancer, and a small molecule, AGI-6780, that potently and selectively inhibits the tumor-associated mutant IDh2/ R140Q is developed.
Journal ArticleDOI
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.
Dimitrios Anastasiou,Yimin Yu,William J. Israelsen,Jian-kang Jiang,Matthew B. Boxer,Bum Soo Hong,Wolfram Tempel,Svetoslav Dimov,Min Shen,Abhishek K. Jha,Hua Yang,Katherine R. Mattaini,Christian M. Metallo,Brian P. Fiske,Kevin D. Courtney,Scott E. Malstrom,Tahsin M. Khan,Charles Kung,Amanda P. Skoumbourdis,Henrike Veith,Noel Southall,Martin J. Walsh,Kyle R. Brimacombe,William Leister,Sophia Y. Lunt,Zachary R. Johnson,Katharine E. Yen,Kaiko Kunii,Shawn M. Davidson,Heather R. Christofk,Christopher P. Austin,James Inglese,Marian H. Harris,John M. Asara,Gregory Stephanopoulos,Francesco G. Salituro,Shengfang Jin,Lenny Dang,Douglas S. Auld,Hee-Won Park,Lewis C. Cantley,Craig J. Thomas,Matthew G. Vander Heiden,Matthew G. Vander Heiden +43 more
TL;DR: It is shown that expression of PKM1, the pyruvate kinase isoform with high constitutive activity, or exposure to published small molecule PKM2 activators inhibit growth of xenograft tumors and support the notion that small molecule activation ofPKM2 can interfere with anabolic metabolism.
Journal ArticleDOI
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine E. Yen,Jeremy Travins,Fang Wang,Muriel D. David,Muriel D. David,Erin Artin,Kimberly Straley,Anil K. Padyana,Stefan Gross,Byron DeLaBarre,Erica Tobin,Yue Chen,Raj Nagaraja,Sung Choe,Lei Jin,Zenon D. Konteatis,Giovanni Cianchetta,Jeffrey O. Saunders,Francesco G. Salituro,Cyril Quivoron,Cyril Quivoron,Paule Opolon,Olivia Bawa,Véronique Saada,Véronique Saada,Angelo Paci,Sophie Broutin,Olivier Bernard,Olivier Bernard,Stéphane de Botton,Stéphane de Botton,Benoit S. Marteyn,Benoit S. Marteyn,Monika Pilichowska,Yingxia Xu,Cheng Fang,Fan Jiang,Wentao Wei,Shengfang Jin,Lee Silverman,Wei Liu,Hua Yang,Lenny Dang,Marion Dorsch,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Scott A. Biller,Shin-San Michael Su +47 more
TL;DR: It is shown that the targeted inhibitor AG-221 suppresses the mutant IDH2 enzyme in multiple preclinical models and induces differentiation of malignant blasts, supporting its clinical development.